BioSpace News Archive

Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2022, and recent business highlights.

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the virtual Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 4:40 p.m. ET, and host investor meetings.

Trevena, Inc.(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the initiation of a Phase 1 proof-of-concept study of TRV045, a novel sphingosine-1-phosphate receptor modulator selective for the S1P receptor subtype 1.

Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.

Patients aged 55 and younger were found to have worse pain, function and quality of life following total knee arthroplasty compared to patients 75 years and older, according to a study presented at the 2023 Annual Meeting of the American Academy of Orthopaedic Surgeons that looked at age-related differences in patient outcomes following TKA.

While the overall number of sports-related injuries is decreasing, the severity of those injuries and the number of head and neck injuries are on the rise, according to a study presented at the 2023 American Academy of Orthopaedic Surgeons Annual Meeting.

With an increase in total hip arthroplasty procedures being performed on younger patients, these patients have historically had poor long-term outcomes associated with implant failure.

Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, announced that it plans to release its unaudited financial results for the fourth quarter and full year 2022 before the U.S. market opens on March 28, 2023.

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced that Noema Pharma, has raised an oversubscribed CHF 103 million Series B financing round.

AlzeCure Pharma AB announced that the company is participating at Redeye Alzheimer Seminar on March 15 at 14:10 CET, where CEO Martin Jönsson will present and answer questions about the latest development in the company.